Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 94

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 94
---
    of Outstanding 
 Options, Warrants 
        and Rights |     | Number of Securities 
  Remaining Available 
  for Future Issuance 
         Under Equity 
   Compensation Plans |
| Equity compensation plans approved by stockholders        |     |                            9,120,304 |     |         $27.01(1) |     |         4,685,891(2) |
| Equity compensation plans not approved by stockholders(3) |     |                            3,219,282 |     |            $40.82 |     |              640,615 |
|                                                           |     |                           12,339,586 |     |            $30.61 |     |            5,326,506 |

| (1) | All option awards, RSUs and PSUs are reflected in this column. The weighted-average exercise price reflects all of these awards collectively. Outstanding RSUs have no exercise price. The weighted-average exercise price for the options, which are primarily the equity awards that have an exercise price, is $31.84. |

| (2) | The equity compensation plans approved by stockholders are described in Note 8 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. Includes 5,063,387 securities available under the 2004 EIP and 263,119 securities available for issuance under the 2015 ESPP as of December 31, 2024. |

| (3) | In May 2020, our Board of Directors approved amendments to the 2004 EIP to permit the granting of up to 750,000 shares of Common Stock as inducement awards to new employees pursuant to Nasdaq Listing Rule 5635(c)(4). This initial pool of shares of Common Stock available for issuance as inducement awards to new employees pursuant to Nasdaq Listing Rule 5635(c)(4) was increased by our Board of Directors in August 2021 by an additional 1,100,000 shares of Common Stock, in May 2022 by an additional 1,600,000 shares of Common Stock and most recently in February 2023 by an additional 1,000,000 shares of Common Stock. The amounts in this line reflect the shares subject to these amendments to the 2004 EIP. The weighted-average exercise price reflects all of the awards outstanding pursuant to this provision of the 2004 EIP collectively